In Zimbabwe, where formal employment is scarce and medical costs are prohibitive, a stark financial choice is being made: affordable funeral policies are vastly outpacing health insurance, reflecting a cultural prioritization of dignified burials over accessible healthcare.
Afya Ltd., a leading medical education group in Brazil, is demonstrating robust financial health with a rising Return on Capital Employed (ROCE) and significant capital expansion. While its stock has faced headwinds, the underlying operational metrics suggest a company efficiently reinvesting for growth, presenting a potential opportunity for value-focused investors.
Amidst a cautiously optimistic economic backdrop in the Eurozone, we spotlight three lesser-known companies with strong fundamentals that investors may be overlooking. From medical supplies to IT services, these firms demonstrate resilience and potential for the year ahead.
The vital Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a tentative step in the implementation of the Israel-Hamas ceasefire. The move, described as largely symbolic for now, offers a glimmer of hope for thousands of Palestinians seeking medical care or a return home.
The vital Rafah border crossing between Egypt and the Gaza Strip reopened Sunday for limited passenger traffic, marking a significant shift after more than two years of closure. The move, part of a ceasefire deal, initiates a tightly controlled process allowing medical evacuations and returns, though humanitarian aid flow remains uncertain.
Israel announces a limited, security-heavy reopening of Gaza's Rafah crossing with Egypt, allowing some medical evacuations while concerns mount over aid access and the safety of returnees.
The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
High Tide Inc. reported record quarterly revenue and profitability in its fiscal Q4 2025, fueled by robust Canadian retail growth. The company outlined aggressive store expansion plans and detailed integration efforts for its new German medical cannabis asset, while also signaling cautious optimism regarding potential U.S. market entry.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Goldman Sachs and Evercore ISI analysts have raised price targets for GE HealthCare Technologies (GEHC), citing a projected market recovery and strong capital expenditure trends by 2026. The medical devices firm is highlighted as a top hedge fund pick.
DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.
Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
Rights groups document a disturbing pattern of Iranian security forces raiding hospitals to arrest injured protesters and the medical personnel treating them, transforming sanctuaries of care into sites of fear and reprisal.
The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
While Medicare provides a crucial safety net at 65, significant gaps in coverage for dental, vision, and long-term care can lead to six-figure annual expenses. Proactive planning with HSAs, specialized insurance, and strategic budgeting is essential to protect retirement savings.
Despite successful ballot initiatives in several states, the path to securing abortion access remains fraught with legal challenges and legislative pushback, as seen in ongoing battles from Missouri to Arizona.
